BiomX To Present at H.C. Wainwright 1st Annual Investor Conference on Bacteriophage
BiomX Inc. (NYSE American: PHGE) announced that CEO Jonathan Solomon will present at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BiomX Inc. (NYSE American: PHGE) announced that CEO Jonathan Solomon will present at the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage on November 30, 2022. The virtual presentation is scheduled for 10:30 AM EST.
BiomX is innovating in the microbiome sector with novel phage therapies targeting specific pathogenic bacteria. The presentation will be available via the Company’s website.
Details
News Market Reaction – PHGE
The recorded move for PHGE in the trading session of this news was +6.50%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NESS ZIONA, Israel, Nov. 29, 2022 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that Jonathan Solomon, Chief Executive Officer of BiomX, will present at the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage on November 30, 2022.
| H.C Wainwright 1st Annual Investor Conference on Bacteriophage | |
| Date & Time: | Wednesday, November 30, 10:30 AM EST (Virtual Presentation) |
| Presenter: | Jonathan Solomon |
| Conference registration: | Link |
The presentation will also be accessible through the Investors section of the Company’s website at https://ir.biomx.com/news-events/ir-calendar.
About BiomX Inc.
BiomX is a clinical-stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria that target and destroy bacteria in the treatment of chronic diseases. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets. For more information, please visit www.biomx.com
BiomX Contacts
Investor Relations:
LifeSci Advisors, LLC
John Mullaly
(617)-698-9253
jmullaly@lifesciadvisors.com
BiomX, Inc.
Anat Primovich
Corporate Project Manager
+972 (50) 697-7228
anatp@biomx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.